Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2147326
ABSTRACT ABSTRACT Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease associated with various health complications and increased mortality. Lifestyle modifications are central to weight...
Relevance: Semaglutide 2.4 mg once weekly was generally well tolerated in adults with obesity, or overweight with comorbidities, without T2D (STEP 1, 3, 4, and 5), and in adults with T2D and overweight or obesity (STEP 2).
Share
-
Dr Hamid3yrObesity is a global health challenge. It is a multifactorial, complex, and progressive disease associated with various health complications and increased mortality
Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2149005
Pharmacotherapy is typically recommended as an adjunct to lifestyle intervention to help achieve and maintain weight loss for those with obesity (body mass index [BMI] of ≥30 kg/m 2) or...
Conclusions/Relevance: The availability of once-weekly semaglutide 2.4 mg for weight management, as an adjunct to increased physical activity and a reduced-calorie diet that is individualized, scientifically supported, and relevant to the patient, represents an important advance in therapeutic options for patients with overweight or obesity.
Share
-
Dr Hamid3yrObesity is a complex, chronic disease that represents a global public health challenge
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2150006
ABSTRACT ABSTRACT Obesity negatively impacts patients' health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea,...
Conclusions/Relevance: Taken together, these are important considerations for primary care when incorporating pharmacotherapy for weight management.
Share
Cardiometabolic risk factors efficacy of semaglutide in the STEP program - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36691308/
People with overweight or obesity often suffer from associated cardiometabolic diseases and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric surgery, and pharmacotherapy. The magnitude of weight loss achieved...
Conclusions/Relevance: Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity, illustrating an effective treatment option for people with overweight (and associated comorbidities) or obesity.
Share
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36655300/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.
Share